What is the mechanism of action of finerenone and how does it differ from spironolactone?

Finerenone vs Spironolactone: Mechanism of Action and Key Differences

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) with greater receptor selectivity and a superior side effect profile compared to spironolactone, a nonselective steroidal MRA that blocks androgen and progesterone receptors in addition to mineralocorticoid receptors.

Mechanism of Action

Spironolactone (Steroidal MRA)

Spironolactone acts as a nonselective and competitive MRA that blocks aldosterone at the mineralocorticoid receptor in the distal convoluted renal tubule 1. However, its steroidal structure causes significant off-target effects:

• Strong affinity for androgen receptors → causes gynecomastia (5.8-52% of males depending on dose) and sexual dysfunction in men 2, 3, 4
• Progesterone receptor agonism → menstrual irregularities in women 3
• Competitive binding at aldosterone-dependent sodium-potassium exchange sites 1

Finerenone (Nonsteroidal MRA)

Finerenone is a selective nonsteroidal MRA with fundamentally different pharmacologic properties 5, 6:

• Greater mineralocorticoid receptor selectivity → minimizes off-target androgen/progesterone effects 5, 7
• Stronger MR-binding affinity than eplerenone 8
• Unique molecular mechanism: Key residues Ser-810 and Ala-773 confer high MR selectivity 7
• More potent anti-inflammatory and anti-fibrotic effects in preclinical models 9

Critical Mechanistic Differences

Finerenone impairs multiple steps of MR signaling that spironolactone does not:

1. Nuclear import blockade: Finerenone delays aldosterone-induced nuclear accumulation of MR more efficiently than spironolactone 7

2. Genomic recruitment prevention: Unlike spironolactone, finerenone inhibits MR and steroid receptor coactivator-1 (SRC-1) binding at gene regulatory sequences and reduces basal MR recruitment 7

3. Tissue distribution: Finerenone shows balanced distribution between heart and kidney, while spironolactone concentrates preferentially in kidneys 9

4. Strict antagonism: Spironolactone can activate the S810L mutant MR (causing severe hypertension), whereas finerenone displays strict antagonistic properties without any agonist activity 7

Clinical Implications

Efficacy

Recent evidence demonstrates comparable efficacy between the two agents 4:

• A 2024 RCT showed finerenone has comparable efficacy to spironolactone in blood pressure control and hypokalemia management in primary aldosteronism 4
• Both achieve similar systolic BP reductions at equivalent MR-blocking doses 3

Safety Profile Advantages of Finerenone

Finerenone demonstrates a superior benefit-risk ratio 5, 9:

• Lower hyperkalemia risk: 17.2% vs 26.4% with spironolactone (P < 0.001) 10
• Minimal hormonal side effects: No gynecomastia or sexual dysfunction due to MR selectivity 5, 7
• Better tolerability: May improve adherence compared to spironolactone 3
• Lower mortality: One real-world study showed 4.4% vs 8.0% all-cause mortality (HR 0.48) 11

Guideline Recommendations

Current guidelines still recommend spironolactone as first-line due to cost and availability 3:

• The 2025 Endocrine Society guideline suggests spironolactone over other MRAs primarily for economic reasons (very low certainty evidence) 3
• However, guidelines explicitly acknowledge that MRAs with greater MR specificity and fewer androgen/progesterone effects may be preferred 3
• The technical remarks state: "all MRAs, when titrated to equivalent potencies, are anticipated to have similar efficacy" 3

Practical Considerations

When to Choose Finerenone Over Spironolactone

Consider finerenone preferentially in:

• Men at risk for gynecomastia or sexual dysfunction (spironolactone causes gynecomastia in 10-52% depending on dose) 2, 3
• Women with menstrual irregularities on spironolactone 3
• Patients with prior spironolactone intolerance due to hormonal side effects 3
• Patients with higher hyperkalemia risk (CKD, diabetes) 10
• Patients requiring better adherence (fewer side effects improve compliance) 3

Dosing Differences

• Spironolactone: 25-50 mg/day initially, maximum 400 mg/day 2
• Finerenone: 20-40 mg/day 12
• Finerenone requires lower doses to achieve equivalent MR blockade due to higher binding affinity 8

Monitoring Requirements

Both agents require identical monitoring 5:

• Potassium and renal function within 1 week of initiation or dose change
• Do not initiate if eGFR <30 mL/min/1.73 m² (spironolactone) or <25 mL/min/1.73 m² (finerenone) 5
• Do not initiate if potassium >5.0 mmol/L 5

Common Pitfalls

1. Assuming equivalent dosing: Finerenone has higher MR-binding affinity; doses are not interchangeable 8

2. Overlooking cost barriers: Spironolactone costs significantly less; finerenone will have highest costs 3

3. Not considering individual tolerability: While guidelines favor spironolactone for cost, shared decision-making should incorporate patient preference regarding side effect risk 3

4. Inadequate dose titration: Both agents should be titrated based on renin response, not just BP control 3